No. PAR-23-284 · National Institutes of Health
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
Not reimbursement-only
“Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.” — From the announcement
- Award range
- Not specified
- Expected awards
- Not specified
- Application deadline
- Sep 25, 2026 23 days left
- Posted
- Sep 22, 2023
- Last verified
- Yesterday
At a glance
AI summaryThis program funds P50 Specialized Programs of Research Excellence (SPORE) grants for state-of-the-art translational cancer research aimed at improving prevention, early detection, diagnosis, and treatment. Applicants are generally expected to be institutions able to do translational research on an organ-specific cancer, a group of related cancers, or a cross-cutting theme such as pediatric cancers or cancer health disparities. New applications must propose at least three projects, each with a human endpoint, and at least one project must include a SPORE-initiated clinical trial; renewal applications may propose two large, collaborative projects instead. The notice does not state an award size or cost-share requirement in the text provided, and some applications may be jointly funded with NIDCR.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments
Program history
USASpending.govAssistance listing 93.121 · Oral Diseases and Disorders Research
Real awards this federal program has made — the whole assistance listing (93.121), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 155 | $429,000 | $306,500 – $571,863 |
| FY 2025 | 277 | $429,000 | $310,295 – $829,259 |
| FY 2024 | 301 | $491,193 | $310,985 – $1,283,003 |
| FY 2023 | 320 | $444,000 | $298,673 – $1,756,575 |
| FY 2022 | 295 | — | — |
| FY 2021 | 305 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 1,653 — award counts are complete.
- TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE $6,128,166 · FY 2023
- THE GENERAL HOSPITAL CORPORATION $4,961,133 · FY 2023
- RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK $4,002,156 · FY 2023
- DANA-FARBER CANCER INSTITUTE, INC. $3,742,682 · FY 2025
- TRUSTEES OF INDIANA UNIVERSITY $3,736,064 · FY 2023
Source: USASpending.gov · refreshed Aug 16, 2026
Assistance listing 93.395 · Cancer Treatment Research
Real awards this federal program has made — the whole assistance listing (93.395), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 316 | $565,152 | $413,691 – $664,926 |
| FY 2025 | 435 | $677,787 | $402,400 – $1,233,798 |
| FY 2024 | 488 | $1,140,586 | $408,966 – $1,897,871 |
| FY 2023 | 522 | — | — |
| FY 2022 | 519 | — | — |
| FY 2021 | 517 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 2,797 — award counts are complete.
- THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER $6,902,371 · FY 2024
- VIRGINIA COMMONWEALTH UNIVERSITY $5,325,147 · FY 2024
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY $4,597,865 · FY 2024
- PRIVO TECHNOLOGIES, INC. $4,499,992 · FY 2024
- FRED HUTCHINSON CANCER CENTER $4,234,248 · FY 2025
Source: USASpending.gov · refreshed Aug 18, 2026